Reports a total income of Rs 1586.47 crores
The Board of Jubilant Pharmova has approved the financial results for the quarter ended March 31, 2021. The company has reported total income of Rs 1586.47 crores during the period ended March 31, 2021 as compared to Rs 1774.93 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs 213.90 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs 309.93 crores for the period ended December 31, 2020. The company has reported EPS of Rs 13.43 for the period ended March 31, 2021 as compared to Rs 19.46 for the period ended December 31, 2020.
In the year ended quarter FY 20-21, the company has reported total income of Rs 6116.18 crores during the 12 months ended March 31, 2021 as compared to Rs 6013.20 crores during the 12 months ended March 31, 2020. The company has posted net profit / (loss) of Rs 835.87 crores for the 12 months ended March 31, 2021 as against net profit / (loss) of Rs.898.24 crores for the 12 months ended March 31, 2020. The company has reported EPS of Rs.52.48 for the 12 months ended March 31, 2021 as compared to Rs.56.39 for the 12 months ended March 31, 2020.
Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and MD, Jubilant Pharmova said, “With the demerger of LSI business into Jubilant Ingrevia effective February 1, 2021, the company’s consolidated results for Q4’FY21 include only one month of LSI business and consolidated results for FY21 include only ten months of LSI business. For FY21 our continuing operations, despite COVID-19 challenges, revenues were stable due to a diverse range of businesses. CDMO and Generics grew though we saw impact on radiopharma and had production impact at the Nanjangud API plant.”